Dr. maryalice stetler stevenson mrd of lymphoproliferative disorder

1. Flow Cytometric Detection of Lymphoma MRD
Maryalice Stetler-Stevenson, M.D., Ph.D.
Director Flow Cytometry Laboratory,
Laboratory of Pathology, NCI, NIH
DEPARTMENT OF HEALTH & HUMAN SERVICES
National Instit
Bethesda, M
Public Health

2. Basis for NCI Approach to Mature
Lymphoma/Leukemia MRD
Mature B-cell and T-cell lymphomas/
leukemias/ have aberrant antigen
expression
The aberrant antigen expression allows
one to detect MRD in the presence of
polyclonal B and T-cells
Currently greater sensitivity is achieved
with B-cell than with T-cell lymphoma.

3. Detection of Mature Lymphoma/Leukemia
MRD with Known Specific IP
CD5+ B-cell neoplasia: CLL, mantle Cell
lymphoma
CD11c+ B-cell neoplasia: Hairy cell
leukemia, Hairy cell leukemia variant,
some splenic marginal zone lymphoma
CD10+ B-cell neoplasia: Follicular
lymphoma, Burkitt lymphoma
Mycosis Fungoides

4. SF08 00901.006
L FSC/SSC
CD19 PerCP Cy5.5
CD5APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
20.89%53.23%
0.91%24.97%
SF08 00901.006
VIABLE by FSC/SSC
CD19 PerCP Cy5.5
SSC-Height
10
0
10
1
10
2
10
3
10
4
0
256
512
768
1024
SF08 00901.006
B CELLS CD19PERCP
CD19 PerCP Cy5.5
CD5APC 10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Gate 66
SF08 00901.006
CD5+CD19+
KAPPA MONO FITC
LAMBDAMONOPE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Detection of CD5 Positive MRD Among
Polyclonal B-Cells
Patient with history of mantle cell lymphoma

5. Detection of CLL MRD Among
Polyclonal B-Cells
CD19 PC7
CD5APC
10 2 10 3 10 4 10 5
102
103
104
105
86.60%0.00%
13.40%0.00%
Kappa-m FITC
Lambda-mPE
10 2 10 3 10 4 10 5
102
103
104
105
No MRD detected 0.006% CLL MRD
SF13 1132 pb MRD 6_01_S-1.fcs
CD3 PerCP
CD19PE
10 2 10 3 104 105
102
103
104
105
75.19%16.64%
0.02%8.15%
SF13 1132 pb MRD 6_06_B-3.fcs
CD19 PC7
CD38v450 10 2 10 3 10 4 10 5
102
103
104
105
SF13 1132 pb MRD 6_06_B-3.fcs
Kappa-m FITC
Lambda-mPE
10 2 10 3 10 4 10 5
102
103
104
105
SF13 1132 pb MRD 6_06_B-3.fcs
CD20 PerCP
CD5APC
10 2 10 3 10 4 10 5
102
103
104
105
SF13 1132 pb MRD 6_06_B-3.fcs
Kappa-m FITC
Lambda-mPE
10 2 10 3 10 4 10 5
10 2
10 3
10 4
10 5

6. FSC-A
SSC-A
0 52429 104858 157286 209715 262144
0
52429
104858
157286
209715
262144
P1
CD3 v500
CD19PC7
10 2 10 3 10 4 10 5
102
103
104
105
32.56%54.90%
0.10%12.44%
CD81 FITC
CD43APC
10 2 10 3 10 4 10 5
10 2
10 3
10 4
10 5
P2
SSC-A
CD43APC
0 52429 104858 157286 209715 262144
102
103
104
105
20.18%
75.79%
3.96%
0.07%
CD20 AH7
CD22PerCPCy55
10 2 10 3 10 4 10 5
102
103
104
105
P4
CD79b PE
CD5v450
10 2 10 3 10 4 10 5
102
103
104
105
P3
Q2
Q4Q3
Q1
Q4-1
Q1-1
Q3-1
Q2-1
Gate 2:Cells in quadrant Q1-1
and within Q1 and Q3
Gate 1:Cells in quadrants
Q1 and Q3
Gate 3:Cells in P1 and
within Q1-1 , Q1 and Q3
Combined Analysis Gate:
Cells in Q1, Q3, Q1-1, P1,
P2, P3 and P4
0.007% of cells in
Combined Analysis Gate
Detection of CLL MRD Among
Polyclonal B-Cells- ERIC Method

7. Detection of CD11c Positive MRD
Among Polyclonal B-Cells
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
8c B CD19 PC7 SSC
CD103 FITC
CD123PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
CD25 PE
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
CD20 AH7
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Kappa-m FITC
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Lambda-m PE
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
CD103 FITC
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Kappa-m FITC
Lambda-mPE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5

8. Detection of CD10 Positive MRD Among
Polyclonal B-Cells
SF12 653 pb_07_B-4.fcs
Kappa-m FITC
Lambda-mPE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_07_B-4.fcs
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
8c B CD19 PC7 SSC
SF12 653 pb_07_B-4.fcs
Kappa-m FITC
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_07_B-4.fcs
Lambda-m PE
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_07_B-4.fcs
Kappa-m FITC
Lambda-mPE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_01_S-1.fcs
CD3 PerCP
CD19PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_01_S-1.fcs VIABLE by FSC/SSC
FSC-A
SSC-A
0 65536 131072 196608 262144
0
65536
131072
196608
262144
8c L FSC SSC
SF12 653 pb_07_B-4.fcs
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF12 653 pb_07_B-4.fcs
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5

9. Mycosis fungoides typically expresses dimmer CD3 than
normal T-cells, and is CD4 positive but is negative for
CD7 and CD26
CD26 is positive in the vast majority of CD4 positive T-cells
ATL- Adult T-cell Leukemia/Lymphoma associated with
HTLV-1 has the same IP but is also CD25 bright
Detection of Mycosis Fungoides MRD:
CD3 APC
CD4PerCP
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD26FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4

10. Detection of Chronic Lymphoproliferative
Disorders Without Specific IP
Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Specific populations normally
present in low numbers
Restricted Populations

11. Detection of T Cell Neoplasia:
Absence of Normal Antigen
75% of mature T cell neoplasms missing a
normal antigen
CD7 is most frequent missing antigen
Commonly absent in subset of normal T-cells
CD5 or CD2 second most common
CD5 absent in subset of gamma delta T cells
CD3 lowest if include cytoplasmic CD3
CD4 and CD8 negative low in mature
tumors

12. Detection of T Cell Neoplasia:
Absence of Normal Antigen
CD3 APC
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD2PE1:1S5.2
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD5APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
69 yo male with enlarged left cervical lymph node.
FNA of lymph node submitted for flow cytometry
Final Diagnosis: PTCL
NOS. Malignant cells
are CD2+, CD3 dim,
CD5-, CD7-, CD4- and
CD8 dim

13. Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Specific populations normally
present in low numbers
Restricted Populations
Detection of Chronic Lymphoproliferative
Disorders Without Specific IP

14. Detection of T Cell Neoplasia:
Presence of Abnormal Antigens
CD3 APC
CD19PerCP
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD19 Expression
FNA: CD19+ PTCL
CD10 Expression
CD5 FITC
CD10APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD5APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD2PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
FNA: AILT:CD3-,
CD5+, CD7-, CD2+,
CD4+, CD10+
Rizzo, Stetler-Stevenson, Wilson, Yuan, Clinical Cytometry, 2009; 76B:142-149
Yuan et al, Human Pathology, 2005;36:784-791

15. A 65 yo woman- multiple erythematous 2 cm to 7 cm tumors
on the upper extremities for about one year. No
lymphadenopathy or organomegaly. FNA of skin lesion sent to
flow cytometry.
CD45 PerCP
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD4 PerCP
CD30FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD5 APC
CD2PEBDS5.2
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD30 FITC
CD2PES5.2
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD30+, CD2+, dim CD4+, dim CD45+ and CD3-, CD5-, CD7- and CD8- Primary Cutaneous CD30+
T cell LPD (ALCL).
Juco, J. Holden, K.P. Mann, L.G. Kelly, S. Li, AJCP, 2003:119:205-212

16. Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Specific populations normally
present in low numbers
Restricted Populations
Detection of Chronic Lymphoproliferative
Disorders Without Specific IP

17. Detection of T Cell Neoplasia:
Abnormal Antigen Intensity
CD5 APC
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD2PE1:1S5.2 10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
T Cell Lymphoma: CD3-, CD7-, CD5 bright, CD2 bright

18. Detection of B Cell Neoplasia:
Abnormal Antigen Intensity
Kappa
Lambda
B Cell Gate
CD19
CD3
CD19
CD3
Lambda
Kappa
Bright CD19 Gate

19. SF08 00901.007
CD20 PerCP
CD5APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
SF08 00901.007
CD22 PE
SSC-Height
10
0
10
1
10
2
10
3
10
4
0
256
512
768
1024
SF08 00901.008
CD20 PerCP
LambdaKALLFitc
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.00% 12.00%
0.00% 88.00%
SF08 00901.007
CD20 PerCP
KappaKALLFitc
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
14.57%0.00%
85.43%0.00%
Detection of B Cell Neoplasia:
Abnormal Antigen Intensity
Dim CD20
and CD5+

20. Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Specific populations normally
present in low numbers
Restricted Populations
Detection of Chronic Lymphoproliferative
Disorders Without Specific IP

21. Abnormally Large T Cells:
FSC-Height
SSC-Height
0 256 512 768 1024
0
256
512
768
1024
CD3 APC
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Large Cells (High FSC) are CD3 dim+, CD4+, CD8dim to -

22. Abnormally Large B Cells:
Kappa
Lambda
Small polyclonal B-cells
Small T-cells
Lambda
Kappa
CD20-PE
FSC-
Size

23. Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Specific populations normally
present in low numbers
Restricted Populations
Detection of Chronic Lymphoproliferative
Disorders Without Specific IP

24. 21yo BM with hepatosplenomegaly: Gamma delta T cell lymphoma
TCRαβ +, CD3+, CD57-, CD56-, CD16+, CD4-, CD8 dim+,
CD7 dim+, CD5-
Detection of T Cell Neoplasia:
Specific Populations

25. Absence of normal antigens
Presence of abnormal antigens
Abnormal antigen intensity
Abnormal sized cells
Increased Numbers of Specific
Populations
Restricted Populations
Detection of Chronic Lymphoproliferative
Disorders Without Specific IP

26. Restricted Populations are
Abnormally Homogeneous
Clonal population-
kappa/lambda or V
Beta

27. Restricted B-Cell Populations:
Kappa/ Lambda
SF12 945 pb_01_S-1.fcs SINGLETS
FSC-A
SSC-A
0 65536 131072 196608 262144
0
65536
131072
196608
262144
8c L FSC SSC
SF12 945 pb_08_B-6+ K-p.fcs SINGLET
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
8c B CD19 PC7 SSC
SF12 945 pb_05_B-2.fcs 8c L FSC SSC
CD19 PC7
CD5PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
59.28% 0.03%
40.68% 0.00%
SF12 945 pb_05_B-2.fcs SINGLETS
CD19 PC7
CD5PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
0.01%93.06%
0.01%6.92%
Kappa-p APC
Lambda-pFITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
0.01% of leukocytes are CD19+. They are all kappa monoclonal and CD5+
CD5 PerCP Cy55
CD38PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
CD43 APC
CD81FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
CD20 AH7
CD22PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5

28. Restricted T Cell Populations: CD4/CD8
Coexpression of CD4 and
CD8 Can be helpful but there
are some normal double + T
CD 8
CD 4CD4
CD8Restricted to CD4 +, CD8 –
Not usually helpful in MRD

29. T-Cell Receptor

30. First DJ joining: joining of the Dβ1 gene segment to one of
six Jβ1 segments or the joining of the Dβ2 gene segment to
one of seven Jβ2 segments
Vβ-to-DβJβ rearrangement then occurs using one of the V
Beta regions
There are a set number of beta V regions (V beta) that can be
used
Generation of Beta Chain by V(D)J Joining

31. T Cell Vβ Repertoire
Each T-cell has a single Vβ domaine used
in its beta chain of the TCR. Clonal T-cells
arise from a single T-cell and have the
exact same Vβ whereas reactive T-cells
have different ones.
There are Vβ-specific antibodies now that
recognize 70% of all individual Vβ
domains
We use an 8 tube panel
3 antibodies in 2 colors

32. CD3 PerCP
CD8APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3+CD8+
Vβ11
Vβ14
Vβ22
FITC
PE CD3 PerCP
CD4APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3+CD4+
TCR Vβ Analysis

33. Utility of V Beta Analysis
FSC/SSC Lymphocyte Gate:
76 yo WF with
chronic anemia-
Hct 29.8,
platelets
120K/MM3, WBC
2.09 with 78.7%
lymphocytes
FSC-Height
SSC-Height
0 256 512 768 1024
0
256
512
768
1024
Gate 1
Consistent with T-Cell LGL: CD3+, CD16-, CD56-, CD57+, CD7 dim to-, CD2+, CD5+, CD8+
Is it clonal?
CD3 APC
CD56+16PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD57FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD5 APC
CD2PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4

34. V beta 9 FITC
Vbeta16PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.43%95.42%
1.86%2.28%
V beta 17.1
V beta 18 FITC
Vbeta20PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.51% 2.48%
94.62% 2.39%
V beta 5.1
V beta 13.1 FITC
Vbeta8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
3.85%92.95%
0.80%2.40%
V beta 13.6
V beta 5.3 FITC
Vbeta3PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
2.34%
V beta 7.1
2.34% 0.64%
73.01% 24.02%
V beta 5.2 FITC
Vbeta12PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.39% 2.67%
95.68% 1.26%
V beta 2
V beta 23 FITC
Vbeta21.3PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
1.94%96.30%
1.46%0.30%
V beta 1
V beta 11 FITC
Vbeta14PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
0.50% 1.43%
96.02% 2.04%
V beta 22
V beta 13.2 FITC
Vbeta7.2PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
2.20%94.66%
0.98%2.16%
V beta 4
The T-Cell LGL is clonal, expressing Vβ 5.3
CD3 PerCP
CD8APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3+CD8+

35. FCI Diagnosis of Minimal T Cell Neoplasia:
CD3 PerCP
CD25PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD26FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4A. Before Treatment
CD3 PerCP
CD7FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD4PerCP
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 PerCP
CD25PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD26FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
B. After Treatment

36. FCI Diagnosis of Minimal T Cell
Neoplasia: V Beta Analysis
CD3 APC
CD56+16PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD19PerCP
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD3 APC
CD4FITC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD7 FITC
CD3PerCP
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
CD26 FITC
CD4PerCP
100 101 102 103 104
100
101
102
103
104
CD3 APC
CD8PE
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Patient with history of T cell neoplasm: CD3 dim, CD7-, CD4-, CD8-, CD26-,
and V Beta 22, post Tx

37. FCI Diagnosis of Minimal T Cell
Neoplasia: V Beta Analysis
Patient with history of T cell neoplasm: CD3 dim, CD7-, CD4-,
CD8-, CD26-, and V Beta 22, post Tx
V beta 3 FITC
Vbeta5.3PE
100
101
102
103
104
100
101
102
103
104
0.00% 1.50%
98.20% 0.30%
Vb 5.3
Vb 3
Vb 7.1
CD3 PerCP
CD4+8APC
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Adjust gate or replace gate to select abnormal cells
V beta 14 FITC
Vbeta11PE
100
101
102
103
104
100
101
102
103
104
Vb 22
Vb 14
Vb 11
0.00% 82.39%
17.01% 0.60%

38. SF14 1070 pb_01_S-1.fcs
8c MNC
CD3 PerCP
CD19PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
1.14% 0.03%
36.34% 62.49%
SF14 1070 pb_04_B-1.fcs 8c MNC
CD20 AH7
CD103FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
1.15%98.17%
0.15%0.54%
SF14 1070 pb_07_B-4.fcs 8c MNC
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF14 1070 pb_07_B-4.fcs 8c MNC
CD19 PC7
CD11cV450
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF14 1070 pb_07_B-4.fcs 8c MNC
Kappa-m FITC
Lambda-mPE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF14 1070 pb_07_B-4.fcs CD19 CD11c HCL?
Kappa-m FITCLambda-mPE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
FCI Diagnosis of Minimal B
Cell Neoplasia:

39. Flow Cytometric Detection of Lymphoma MRD